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pen accessAbstract Background: Iliac crest (IC) pain accompanies IC grafting in spine surgery. The study
evaluates the effectiveness of ropivacaine 0.4% iliac crest iontophoresis as compared to infusion
through an IC catheter.
Methods: Thirty patients, 10 in each group, undergoing lumbar spine surgery had an intraoperative
epidural block performed and initiated with 20 ml ropivacaine, 0.5% (100 mg) at termination of
surgery and after 6 h maintained for 48 h (t48) at 10 ml/h with ropivacaine, 0.2%. Thirty millilitres
NaCl, 0.9% (Group I ‘‘placebo group’’ and Group II ‘‘ropivacaine iontophoresis group’’) or 30 ml
ropivacaine, 0.4% (Group III ‘‘ropivacaine IC catheter group’’) was also administered via an intra-
operatively placed IC catheter. At t0, and for 48 h, 5 ml/h ropivacaine, 0.4% was administered via
the IC catheter in Group III. In Group II, 30 ml ropivacaine, 0.4% iontophoresis was done using
iontocare iontophoresis device. At t0 and for 48 h, 5 ml 0.4% ropivacaine iontophoresis was done at
iliac crest site every hour using the iontocare device in Group II. Any further pain was controlled
using intravenous morphine 0.1% in 5 mg increments. Pain assessment scores at IC site and at sur-
gical site were evaluated at rest and at motion every 8 h for 48 h and after 4 m. Unbound and total
plasma ropivacaine, morphine consumption, and patient satisfaction were evaluated.ail.com (T. Rushdi).
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262 T. Rushdi et al.Results: At IC site, signiﬁcant lower pain scores were elucidated in Groups II and III as compared to
Group I at rest and at motion in the initial 48 h and at motion after 4 m. Plasma unbound ropiva-
caine was higher signiﬁcantly in Group III at t48 when compared with Group I. Morphine consump-
tion was lower signiﬁcantly in Groups II and III at 24 and at 48 h when compared with Group I.
Conclusions: Ropivacaine IC iontophoresis provides safe effective analgesia for the initial 48 h and
after 4 m.
ª 2011 Egyptian Society of Anesthesiologists. Production and hosting by Elsevier B.V.
Open access under CC BY-NC-ND license.1. Introduction
Spine surgeries are consideredprocedures associatedwithpostop-
erative considerable discomfort and pain [1]. Moreover, they fre-
quently mandate grafting from iliac bone, with two agonizing
patient foci of pain. Continuous local anesthetic application via
epidural placed catheter is regarded a postoperative lumbar spine
surgery pain control establishedmodality [2,3].Although the pain
at the iliac donor graft site usually persists throughout the initial
postoperative weeks, the pain in its site may not resolve and
may represent a signiﬁcant postoperative morbidity source [4].
Moreover, pain incidences were reported after harvesting iliac
crest (IC) bone graft revealing 29%, 38%, and 19% at 3 months,
6 months, and2 years, respectively [1,5]. Lidocaine iontophoresis,
which is the percutaneous delivery of charged drugs using low le-
vel electrical current, was proved to be potentially effective, safe
and with no systemic bioavailability [6].
Local morphine administration and wound bupivacaine
inﬁltration were used to be performed for pain control in the
donor site at the IC [7].
Although the pain mechanism in IC donor site is still unre-
vealed, some periosteal and muscular postulations arose in
relation to abductors stripping from bony ilium. It was also
observed that pain increases at 3 months during ﬂexion of
the thigh toward the thorax and pain of neuropathic origin
was postulated to be due to superior cluneal, the lateral femo-
ral cutaneous or ilioinguinal nerves injury [4].
Grafted bone from IC is also often undergone in anterior
cervical fusion where donor IC site pain may frequently be
more agonizing than the pain at the primary site of operation.
As local anesthetic direct site inﬁltration after bone harvesting
is one method used for pain relief, patients who were adminis-
tered bupivacaine needed less morphine and reported lower
average length of hospital stay. This clinically implies that lo-
cal anesthetic usage for the relief of the pain at the donor site is
an effective and safe modality [7].
The study aimed at evaluating the analgesic safety and efﬁ-
cacy of ropivacaine 0.4% iontophoresis as compared to infusion
via an IC catheter for 48 h at the site of harvested bone graft in
patients undergoing lumbar spine surgery. Additionally, the do-
nor IC site pain was assessed at 4 months after surgery.
2. Methods
After obtaining local hospital ethics committee approval and
written informed consents, 30 adult patients, scheduled to un-
dergo elective lumbar spine surgery from a dorsal approach
using IC bone grafts, were enrolled in this prospective, ran-
domized, double-blind study. Patients (American Society of
Anesthesiologists status I or II; age, 20–70 years; weight,
55–110 kg; height, 150–190 cm) were eligible for inclusion ifthey had no known sensitivity to local anesthetics or mor-
phine, were not pregnant, did not have a pacemaker, did not
receive ropivacaine before surgery for at least 7 days and did
not receive any opioid or antiinﬂammatory nonsteroidal drug.
Failure to place an epidural catheter intraoperatively was also
regarded as an exclusion criterion for the study.
This model is a standardized surgery mandating a similar
amount of iliac bone grafting and with both surgical locations
receiving same pain relieving drug. Patients were handed a
number between 1 and 30 by picking up a sealed envelope
enclosing the number. Patients were divided into three groups
with 10 patients in each group. Each patient’s attributed num-
ber was given to a pharmacist, who was indulged in preparing
the anesthetic pack (for bolus and for maintenance) of the
speciﬁed concentration of the ropivacaine or the placebo, in
accordance to the randomization special list. On the surgery
day, patients’ premedication with 0.2 mg/kg midazolam was
orally given 90 min before induction of anesthesia. Induction
of general anesthesia was initiated using propofol 1.5–
2.5 mg/kg and maintained using propofol 4–12 mg/kg/h.
0.6 mg/kg rocuronium in addition to 0.2 mg fentanyl were
administered to facilitate intubation of the trachea. Each pa-
tient was meticulously turned into the prone position and spine
surgery was undergone. Via an oblique surgical incision from
proximal–medial to distal–lateral perpendicular to the poster-
ior IC, bone graft was harvested. After exposing adequate
ﬁeld, an osteotome was used to cut through the IC exposing
the iliac bone marrow cavity. Before wound closure, a foam
pad self-resorbing dressing was directly placed over the bone.
Tuohy 18-gauge needle (Periﬁx B. Braun Melsungen AG,
Melsungen, Germany) was used for tunneling the skin lateral
to the incision in order to allow placement of a 20-gauge cath-
eter directly in contact with the dressing. Then this catheter
was secured to skin via sutures and adhesive dressing after
completing the surgery. A thin adhesive dressing, covering
only the suture line, was also placed at IC graft site allowing
iontophoresis to be performed at the IC site from all around
the suture line. At the termination of the lumbar spine surgical
intervention, a multiple-hole epidural catheter (B. Braun,
Melsungen, Germany) was introduced by the orthopedician
either under direct visualization (if epidural space was opened
during the surgical procedure) or with the loss-of-resistance
technique using an 18-gauge Tuohy needle. The catheter was
tunneled inside the epidural space for 3 cm and secured with
a surgical knot to the skin. The catheter was tested by aspira-
tion and the administration of a test dose consisting of 3 ml of
bupivacaine, 0.5% with epinephrine (1:200,000). Initiation of
the epidural block with 20 ml of ropivacaine, 0.5% (i.e.,
100 mg) was done in all studied patients. Starting at 6 h after
the initial epidural block, continuous epidural analgesia, with
0.2% of ropivacaine at an infusion rate of 10 ml/h, was also
administered to all patients.
Figure 1 Iontocare device.
Ropivacaine 0.4% iontophoresis versus continuous catheter infusion 263In Group I ‘‘placebo group’’, 30 ml of NaCl, 0.9% was
administered via the IC catheter at the end of surgery followed
by a continuously infused solution of NaCl, 0.9% at an infu-
sion rate of 5 ml/h, and corresponding to the t0 of the study
and for 48 h. Thirty millilitres NaCl, 0.9% iontophoresis was
done at IC site at the end of surgery followed by 5 ml NaCl,
0.9% iontophoresis, at t0 and every hour for 48 h.
In Group II ‘‘ropivacaine iontophoresis group’’, 30 ml of
NaCl, 0.9% was administered via the IC catheter at the end
of surgery followed by a continuously infused solution of
NaCl, 0.9% at an infusion rate of 5 ml/h, at t0 of the study
and for 48 h. Thirty millilitres ropivacaine, 0.4% iontophoresis
was done at IC site at the end of surgery followed by 5 ml,
0.4% ropivacaine iontophoresis, at t0 and every hour for 48 h.
In Group III ‘‘ropivacaine IC catheter group’’, 30 ml of
ropivacaine, 0.4% was administered via the IC catheter at
the end of surgery followed by a continuously infused solution
of 0.4% ropivacaine at an infusion rate of 5 ml/h, at t0 of the
study and for 48 h. Thirty millilitres NaCl, 0.9% iontophoresis
was done at IC site at the end of surgery followed by 5 ml
NaCl, 0.9% iontophoresis, at t0 and every hour for 48 h.
Iontophoresis was done using iontocare (Luventas-Medi-
cal, Germany) iontophoresis device (Fig. 1) and a sterile
sprayer after skin sterilization using sterillium (Bode Chemie,
Hamburg). The sterilized device roller, representing anode, is
rolled over the skin at IC site of the operated upon side holding
the device, from its sides, representing cathode, in one hand
while touching the patient abdomen with the other hand to
close the circuit. The device is adjusted at 4 mA and the ion
switch is turned to the ‘‘positive’’ ion side. The device is shown
to be operating when a blue light is lit on the light-emitting
diode (LED) of the device.
Patients were transferred after tracheal extubation to the
Post Anesthesia Care Unit (PACU).
Any further pain was controlled using intravenous
morphine 0.1% in 5 mg increments and reported in the patient
record. All the patients were instructed to receive 25 mg oral
rofecoxib in addition to 2 g oral paracetamol each day for pain
management within the 3 postoperative weeks if pain persisted
after discharge.2.1. Data assessment
A nurse not enrolled in or aware of the study protocol was
responsible for evaluating pain in the operated site at IC and
the spine (from t0 and every 8 h till t48, i.e., end of study) using
the visual analog scale (from 0 mm= no pain to 100 mm=
worst pain imaginable) at state of rest and during state of mo-
tion. The state of motion was elicited with thigh ﬂexing toward
thorax and this test was regarded as adequate when the thigh of
the patient was in direct contact with his abdomen. All attacks
of nausea, vomiting, or pruritis were also reported. Amount of
consumption of morphine was reported at t24 and at t48. Daily
observation of the IC catheter and epidural catheter for any
inﬂammatory signs or signs of infection was done. Patients
were requested to rank their satisfaction starting from 0, i.e.,
absolutely dissatisﬁed till 10, i.e., absolutely satisﬁed on the
day after termination of the study. Four months after surgery,
all studied patients were observed separately by an anesthesiol-
ogist and a surgeon. This was both to evaluate the pain at state
of rest and during state of motion at the operated sites at IC and
the spine, via the visual analog scale (0–100 mm) by the anes-
thesiologist and to perform neurologic evaluation comprising
numbness, paresthesias and dysesthesias for damage of the ili-
oinguinal, lateral femoral cutaneous and superior cluneal
nerves by the surgeon.
2.2. Blood ropivacaine sampling
Blood concentrations of ropivacaine were reported at t0, at
t24, as well as at t48. Ten millilitres blood samples were re-
trieved in heparinized test tubes for unbound and total plasma
ropivacaine concentration determination. Centrifugation (at
3000 rpm for 10 min) for plasma separation was done at room
temperature and within 60 min after collection. Plasma was
stored at 20 C till performing drug assay. Gas chromatogra-
phy was used for plasma total ropivacaine concentration deter-
mination while the plasma unbound ropivacaine concentration
was determined using liquid chromatography with mass spec-
trometric detection after sample ultraﬁltration.
2.3. Statistical analysis
In accordance to prior studies, pain severity at state of rest in
this operative context was unbearable in 20% of patients
receiving morphine via a patient-controlled analgesia device
in the initial 48 h postoperatively. A power analysis was indic-
ative of a size of a sample of 10 patients per group to sufﬁ-
ciently have an 80% power at 95% signiﬁcance level.
Mean ± SD was used to present the data unless otherwise
was stated. Parametric variables were analyzed via Analysis
of Variance. Mann–Whitney U-test with Bonferroni correction
for multiple comparisons was used to analyze the pain scores.
Fisher exact test was used to analyze adverse effects. P value of
less than 0.05 was regarded signiﬁcant.
3. Results
All studied patients fulﬁlled the protocol of the study.All groups
were considered comparable regarding age, height, sex, weight,
and surgical procedure duration (Table 1). All epidural analge-
sia catheters were successfully instituted, with no technical or
Table 3 VAS at site of the iliac crest in state of rest as well as
during the state of motion after 4 months in the three studied
groups. Values are presented as mean ± SD.
At state of rest During state of motion
Group I 14 ± 6 36 ± 10
Group II 6 ± 5 12 ± 7*
Group III 4 ± 2 11 ± 8*
VAS = visual analog scale from 0 = no pain to 100 = worst pain
imaginable.
* Signiﬁcant difference between the studied group and Group I
(P< 0.05).
264 T. Rushdi et al.disconnection problems throughout the study course.
Signiﬁcant lower pain scores were elicited at the IC donor site
at state of rest and during the state of motion in the ropivacaine
groups (Groups II and III) when compared with Group I eval-
uated every 8 h up till t48 (Table 2A and B). Reports at the
4 months revealed that pain at the IC donor site in the state of
motion (aching pain type) was lower signiﬁcantly in the Groups
II and III in comparison to Group I. At the state of rest, pain
scoring was comparable in all groups (Table 3). No achievable
signiﬁcant difference was elicited among the studied groups as
regards pain in the spine surgical site at the state of rest or during
the state of motion, either throughout the initial 48 h postoper-
atively (Table 4A) or after 4 months (Table 4B). In Group I, the
morphine consumption was increased signiﬁcantly in compari-
son to the ropivacaine studied groups (Groups II and III) at
24 as well as at 48 h (Table 5). The incidence of nausea and vom-
iting, which occurred in 7, 5, and 4 of the studied patients in
Groups I, II, and III, respectively, revealed no statistically sig-
niﬁcant difference. Pruritis was reported in 6, 3, and 4 of the
studied patients in Groups I, II, and III, respectively, reaching
no signiﬁcant difference as well. There were not any observed
signs of infection or inﬂammation at the IC catheter point of
skin puncture in any of the studied patients. Ropivacaine groups
(Groups II and III) revealed signiﬁcantly greater patient satis-
faction as compared to Group I. Patient satisfaction
(mean ± SD) was 4 ± 2, 7 ± 1, and 9 ± 1 in Group I, II,
and III, respectively. The plasma total ropivacaine concentra-
tions were comparable in the three studied groups of patients
at all studied times (Table 6A). The unbound ropivacaine frac-
tion was higher in the ropivacaine groups (Groups II and III)
than Group I at t0 and t24, as well as at t48, but only at t48
was higher signiﬁcantly in Group III in comparison to GroupTable 1 Patient characteristics.
Group I (n= 10
Sex, male/female 8/2
Age, years (mean ± SD) 26 ± 3
Weight, kg (mean ± SD) 79 ± 5
Height, m (mean ± SD) 1.68 ± 8
Operated upon site, right/left 3/7
Surgery time, min (mean ± SD) 77 ± 29
Table 2 VAS at site of the iliac crest in state of rest (A) as well as d
postoperatively (=t0) and then every 8 h up till t48. Values are pres
t0 t8 t16
A
Group I 40 ± 20* 19 ± 12* 18 ± 11*
Group II 12 ± 8 7 ± 3 7 ± 5
Group III 9 ± 12 6 ± 5 7 ± 4
B
Group I 58 ± 25* 32 ± 20* 29 ± 13*
Group II 12 ± 10 9 ± 6 9 ± 7
Group III 12 ± 8 8 ± 7 9 ± 4
VAS= visual analog scale from 0 = no pain to 100 = worst pain imagi
* Signiﬁcant differences between the studied group and the other groupsI (Table 6B). Four months postoperatively, there were no
patients revealing any signs of neurologic injury of the ilioingui-
nal, the lateral cutaneous, or the superior cluneal nerves. More-
over, there were no patients revealing paresthesias or numbness.
4. Discussion
This study reveals that, as compared to placebo, the 0.4%
ropivacaine IC iontophoresis group of patients achieves signif-
icantly better postoperative pain control at the IC donor site
both at the state of rest as well as during the state of motion,
achieves signiﬁcantly lower consumption of morphine as well
as signiﬁcantly higher satisfaction of patients and without sig-
niﬁcantly higher total or unbound ropivacaine plasma concen-
tration at any time. Furthermore, the advantageous impact on
pain remained available during the state of motion 4 months
postoperatively in those patients.) Group II (n= 10) Group III (n= 10)
7/3 6/4
29 ± 4 25 ± 4
85 ± 7 75 ± 11
1.65 ± 4 1.70 ± 5
4/6 7/3
84 ± 19 82 ± 31
uring the state of motion (B) in the three studied patient groups
ented as mean ± SD.
t24 t32 t40 t48
18 ± 13* 17 ± 12* 16 ± 11* 18 ± 12*
4 ± 4 4 ± 1 6 ± 4 5 ± 4
4 ± 3 3 ± 3 4 ± 3 4 ± 2
30 ± 19* 30 ± 13* 29 ± 16* 26 ± 15*
8 ± 4 7 ± 3 6 ± 5 7 ± 5
7 ± 6 6 ± 4 6 ± 4 7 ± 4
nable.
(P< 0.05).
Table 4 Postoperative pain at the spine operative site expressed as VAS in state of rest (A) as well as during the state of motion (B) in
the three studied patient groups postoperatively (=t0) and then every 8 h up till t48. Values are presented as mean ± SD.
t0 t8 t16 t24 t32 t40 t48 4 months
A
Group I 1 ± 2 2 ± 3 3 ± 3 4 ± 3 3 ± 5 4 ± 3 5 ± 6 12 ± 5
Group II 1 ± 3 1 ± 2 2 ± 3 6 ± 5 4 ± 6 3 ± 4 3 ± 6 11 ± 4
Group III 2 ± 4 1 ± 2 4 ± 3 4 ± 1 4 ± 3 3 ± 5 4 ± 2 9 ± 3
B
Group I 3 ± 5 5 ± 7 7 ± 10 7 ± 9 6 ± 4 7 ± 8 9 ± 11 20 ± 8
Group II 4 ± 4 2 ± 3 7 ± 7 7 ± 10 4 ± 1 8 ± 10 8 ± 5 16 ± 5
Group III 4 ± 6 4 ± 6 6 ± 8 11 ± 12 5 ± 4 7 ± 9 7 ± 10 17 ± 6
VAS= visual analog scale from 0 = no pain to 100 = worst pain imaginable.
Table 5 Mean postoperative consumption of morphine (in
milligrams) in the three groups of studied patients at 24 h and
at 48 h postoperatively. Values are presented as mean ± SD.
At 24 h At 48 h
Group I 28 ± 14* 47 ± 19*
Group II 12 ± 8 18 ± 12
Group III 13 ± 4 17 ± 10
* Signiﬁcant differences between the studied group and the other
groups (P< 0.05).
Ropivacaine 0.4% iontophoresis versus continuous catheter infusion 265In the current study, ropivacaine was used because, in com-
parison to the other long lasting and amino acid local anesthet-
ics, it carries the least neurotoxicity as well as the greatest
safety margin [8]. The 0.4% concentration was the ropivacaine
concentration used at the IC site via iontophoresis and
through IC catheter as a preliminary conducted pilot study re-
vealed good postoperative pain control at the IC donor site at
this concentration.
To our knowledge, this study is amongst the ﬁrst studies
eliciting the efﬁcacy of 0.4% ropivacaine iontophoresis at the
iliac crest donor site in patients undergoing lumbar spine sur-
gery with IC graft.
Functional complications encountered by adults who per-
formed IC grafting entailed that 37.9% of those patients did
report pain at 6 months in the postoperative period. Thereafter
pain incidence was reduced, where 18.7% of the patients con-
tinued reporting pain after more than 2 postoperative years [1].
Schenk et al. proved that after major spine surgery, continuous
epidural ropivacaine analgesia resulted in signiﬁcantly superior
analgesia and patient satisfaction than intravenous morphine
analgesia [2].
Lidocaine iontophoresis was reported to be an effective
noninvasive local anesthesia for laser surgery of superﬁcial
skin lesions [9]. It has also been proved effective in topical
anesthesia in children and in adults [10].
It was shown by Knudsen et al. that the tolerated maximum
dose for CNS symptoms was more in 9 out of 12 subjects after
ropivacaine and after bupivacaine was more in 3 subjects [11].
It has been documented that correctly placed ‘surgical’ epidu-
ral catheters are effective means of good analgesia after poster-
ior spinal surgery [12]. This is advantageous in this study foralmost absolutely aborting the pain originating other than that
arising from the IC donor site.
The beneﬁcial outcomes of local anesthetics iontophoresis
have been illustrated by variable clinical studies [9,10]. In a
study by Cowan et al. [7] positive results were reported after
repeated applications of 0.25% bupivacaine boluses for IC do-
nor site pain. Gundes et al. [13] revealed that addition of mor-
phine to bupivacaine achieved a better control of pain in
comparison to bupivacaine solely. Efﬁcacious control of pain
in the acute phase had a favorable outcome on long-term dys-
esthesia and pain, which constitutes the main issues that pa-
tients complain of postbone grafting from iliac crest [13]. The
advantageous impact of this management was still evident after
3 months.
The favorable outcome of less chronic pain at the donor
location encountered in the current study and in another study
[13] is suggestive of a chronic pain-relieving effect where a dim-
inution in spinal cord hyperexcitability is produced by a quick
decrease in afferent noxious input [14]. Nevertheless, this mat-
ter is under controversy [15]. Furthermore, as revealed by
Kelly et al. [16] the changeable patient features relative to
the operative noxious stimulus mandated individualization of
the method chosen. Additionally, multimodal pain-relieving
methods appear more efﬁcient as compared to a sole-drug
management [17].
In the present study, no patient got any clinical manifesta-
tions of pain of neuropathic nature, plus no sensory disorders
were encountered. The advancement of the IC catheter in a
swab on the periosteum appears suitable as the neurosensory
pain ﬁbers resides in high condensation in the periosteum,
while ﬁne nonmyelinated as well as myelinated ﬁbers escort
vessels to the inside of the bone [18,19].
In the ropivacaine groups of studied patients (Groups II and
III), patients were given 0.4% ropivacaine at a rate of 5 ml/h at
the iliac crest. The mean blood unbound ropivacaine concen-
trations in Group III given the 0.4% ropivacaine through IC
catheter were 0.051, 0.061, and 0.090 mg/l at t0, t24, and t48,
respectively, while in Group II given the 0.4% ropivacaine ion-
tophoresis at IC site were 0.053, 0.059, and 0.039 mg/l at t0, t24,
and t48, respectively. These blood levels stay well behind the
levels reported by Knudsen et al. regarding early central
nervous toxicity signs of 0.15 mg/l [11].
In the clinical study by Knudsen et al., a central nervous
system threshold for toxicity was evident at a mean plasma free
level of almost 0.6 mg/l for ropivacaine as well [11].
Table 6 Plasma total (A) and unbound (B) concentration of
ropivacaine in the three groups of studied patients at 24 h and
at 48 h postoperatively. Values are presented as mean ± SD.
t0 t24 t48
A
Group I 0.60 ± 0.3 1.2 ± 0.4 1.5±.07
Group II 0.81 ± 0.2 1.4 ± 0.8 1.8 ± 0.2
Group III 0.80 ± 0.5 1.6 ± 0.3 1.8 ± 0.7
B
Group I 0.032 ± 0.035 0.028 ± 0.015 0.020 ± 0.012
Group II 0.053 ± 0.032 0.059 ± 0.021 0.039 ± 0.028
Group III 0.051 ± 0.048 0.061 ± 0.011 0.090 ± 0.110*
* Signiﬁcant difference between the studied group and Group I
(P< 0.05).
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rent study at t48 in Group III being given ropivacaine 0.4%
through IC catheter was the only blood level achieving
signiﬁcantly higher blood levels as compared to Group I ‘‘pla-
cebo group’’.
The occurrences of pruritis, nausea as well as vomiting were
comparable in the three studied groups in spite of the lower
consumption of morphine plus the better control of pain in
the ropivacaine groups of patients. The major endpoint in
the present investigation was the pain score, and thus, the
investigation was presumably underpowered in unveiling a dis-
similarity in-between the three studied groups as regards the
side effects.
The current study reveals that 0.4% ropivacaine iontophore-
sis at the iliac crest harvest site can diminish the occurrence as
well as the severity of initial acute and later chronic pain at
the iliac crest donor site postlumbar spine surgery with IC graft.
This was coupled with a reduced pain score in the early postop-
erative time, diminished consumption of morphine, higher level
of satisfaction of patients, few side effects as well as a reduced
pain score during state of motion four months postoperatively.
Those favorable results were comparable to those elicited in pa-
tients given 0.4% ropivacaine through IC catheter but without a
signiﬁcantly higher unbound ropivacaine blood level as com-
pared to control group 48 h postoperatively.
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